BioSpace News Archive

The global regulatory affairs outsourcing market size is expected to expand around USD 16.6 billion by 2030 from USD 7.11 billion in 2022 with a CAGR of 10.2% from 2021 to 2030.

According to Nova one advisor, the global RNA Analysis market size was estimated at USD 11.19 billion in 2022 and is projected to hit around USD 42.35 billion by 2030, growing at a CAGR of 16.62% during the forecast period 2022 to 2030.

Pumas-AI, a science-first organization that turns data into life-saving decisions faster, announced today that Co-Founder and Chief Scientific Officer (CSO) Vijay Ivaturi, PhD, has been elected as the next President of the International Society of Pharmacometrics (ISoP).

Seven leading health associations announced a new collaboration to support diabetes care in the primary care and family practice setting.

A series of new Fast Track designations have been handed out by the United States Food and Drug Administration (FDA) this week, causing a flurry of activity in the markets for the worthy recipients.

Acutus Medical, Inc., an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, granted equity awards on December 1, 2022 that were approved by the Compensation Committee of its Board of Directors under Company’s 2022 Inducement Equity Incentive Plan, as a material inducement to employment to 3 individuals hired by Acutus in November 2022.

Valitor, a biotechnology company engineering better medicines to conquer drug limitations, announced that its president and chief scientific officer, Wesley Jackson, Ph.D., will present at the Ophthalmology Innovation Source XII Summit in San Diego, CA on December 3, 2022.

Cytokinetics, Incorporated (Nasdaq: CYTK) today announced one poster presentation at the Virtual 33rd International Symposium on ALS/MND taking place online from December 6, 2022 - December 9, 2022 relating to survival predictions from FORTITUDE-ALS (Functional Outcomes in a Randomized Trial of Investigational Treatment with CK-2127107 to Understand Decline in Endpoints – in ALS), the Phase 2 clinical trial of reldesemtiv in ALS.

TCR2 Therapeutics Inc., a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from solid tumors, announced the Compensation Committee of the Board of Directors of TCR2 approved the grant of inducement stock options covering an aggregate of 24,400 shares of TCR2’s common stock to 3 new non-executive employees.

Pipeline Therapeutics, a clinical-stage biopharmaceutical company pioneering precision neuroregeneration, announced that management will participate in the 2022 RBC Capital Markets Healthcare Private Company Virtual Conference.